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Context: Human securin pituitary tumor-transforming gene
(hPTTG) is overexpressed in a variety of primary neoplasias, includ-
ing differentiated thyroid cancer (DTC).
Objective: The objective of this study was to examine the immuno-
histochemical expression of hPTTG in DTC and its association with
known prognostic factors.
Design: hPTTG expression was analyzed by immunostaining on
paraffin-embedded tissues. Clinical data were used to determine
any associations between the expression of hPTTG and prognostic
variables of DTC. A median follow-up of 43 months allowed us to
analyze the persistence of disease and the response to radioiodine
therapy.
Setting: The study was conducted at a tertiary university hospital.
Patients:Ninety-five patients undergoing surgical resection for DTC
(n  60) or benign nodular thyroid disease (n  35) were studied.
Main Outcome Measure: The main outcome measure was the as-
sociation between hPTTG expression and prognostic factors in DTC.
Results: Among DTC cases, 21 (35%) had low and 39 (65%) had high
hPTTG immunostaining. Adjacent nonneoplastic thyroid tissue was
largely unstained. Among benign nodular thyroid disease cases, immu-
nostaining was detected focally in eight (22.8%). A significant association
was found between hPTTG expression and the presence of nodal (P 
0.01) or distant metastases (P  0.05). A significant association with
TNM was also found, because 83.3% of advanced TNM stages showed
elevated hPTTG (P  0.05). The association between hPTTG overex-
pression and decreased radioiodine uptake during follow-up was also
significant (P  0.05). The expression levels of hPTTG were confirmed
as an independent prognostic factor for persistent disease (relative risk,
3.0; 95% confidence interval, 1.1–8.7; P  0.05).
Conclusions: Immunohistochemical analysis of hPTTG is of poten-
tial value in the determination of tumor aggressiveness in DTC.
(J Clin Endocrinol Metab 91: 1404–1409, 2006)
THYROID CANCERS ARE the most common endocrinemalignancies (1). Papillary and follicular thyroid can-
cer, together referred to as differentiated thyroid carcinoma
(DTC), comprise 90% of thyroid cancers and account for 70%
of thyroid cancer-related deaths (2). Although DTC is usually
curable when discovered at an early stage, a significant per-
centage of individuals have persistent or recurrent disease
(3). Retrospective analysis of prognostic factors revealed that
age above 45 yr, male sex, tumor size over 4 cm, vascular
invasion, histological grade, lymph node and/or distant me-
tastases, and certain tumor subtypes are predictive of per-
sistent or recurrent disease and cancer death (4). However,
disease free-status and survival cannot be assured by a low
stage in most staging systems, thus providing imperfect
guidance in selecting therapy (3, 5). Specific molecular mark-
ers that provide prognostic value would be extremely useful
in the design of individualized therapies for DTC. Several
molecular events have been implicated in the pathogenesis
of hyperplastic and neoplastic thyroid lesions (6), but mo-
lecular prognostic markers are still lacking in clinical
practice.
Human pituitary tumor-transforming gene (hpttg) product
is a 22-kDa protein that is abundantly expressed in many
tumor cell lines and is tumorigenic in vivo (7, 8). The expres-
sion of hPTTG is regulated through the cell cycle, peaking at
mitosis, and is phosphorylated by cell division cycle 2 (9).
hPTTG has been identified as a vertebrate securin on the
basis of its analogy to yeast securins Pds1 and Cut2 (10), and
therefore, primary hPTTG function is related to the control
of sister chromatid separation to opposite spindle poles.
Based on this functional activity, genomic imbalance as a
result of chromosome missegregation is a rationale for the
oncogenic potential of dysregulated hpttg expression. hpttg is
expressed at high levels in human pituitary adenomas (11,
12), but also in other epithelial malignant tumors, including
breast, lung, ovary, and colorectal tumors (12–14), as well as
in hemopoietic neoplasias (7, 15). Most importantly, hpttg
expression has been correlated with lymph node invasion in
colorectal cancer; therefore, it might be a prognostic molec-
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ular marker (14). Recently, increased hpttg expression has
been demonstrated in thyroid carcinomas (16, 17), and an
association between hpttgmRNA and early tumor recurrence
has been found in a series of patients (17). In the present work
we aimed at analyzing the expression of hPTTG in a large
series of thyroid tumors comprising DTCs, follicular adeno-
mas, and multinodular goiters, using a specific rabbit poly-
clonal anti-hPTTG antibody and immunohistochemical
methods. We also aimed at studying the association of tissue
hPTTG overexpression with established prognostic factors
and its usefulness as a prognostic marker of persistent dis-
ease in DTC.
Patients and Methods
Patients and tissue samples
Thyroid tissue samples were retrieved from archival material of a
series of 95 patients undergoing surgical resection for DTC (n  60) or
benign nodular thyroid disease (BNTD; n  35). All procedures were
conducted in accordance with the guidelines of the local ethical com-
mittees. DTC included 47 papillary carcinomas (PTC; 33 of conventional
histology, eight of the tall cell variant, three of the follicular variant of
PTC, and three diffuse sclerosing PTC) and 13 follicular carcinomas
(FTC; 10 of conventional histology, two of the insular variant, and one
oxyphilic FTC). BNTD cases included 22 multinodular goiters and 13
follicular adenomas. All specimens were formalin fixed and paraffin
embedded according to routine protocols. Patients’ demographics, thy-
roid function, and the presence of autoantibodies were recorded. TNM
staging of the tumor at presentation (18) was recorded in all cases of DTC
inasmuch as precise information about tumor size, tumor extent beyond
the thyroid capsule, lymph node status, and distant metastasis was
available from medical records (Table 1). Follow-up protocols were
conducted according to international standards (19). For patients who
had undergone total thyroidectomy and radioiodine remnant ablation,
a TSH-stimulated 131I diagnostic whole body scan (DWBS) was per-
formed 12 months after ablation. Thyroglobulin (Tg) was measured
every 6 months after thyroid hormone suppression of TSH and in every
DWBS, after T4 withdrawal. Tg and anti-Tg autoantibodies (TgAb) as-
says were performed simultaneously. Serum Tg was measured by im-
munoradiometric assay (DiaSorin, Saluggia, Italy) with a functional
sensitivity of 0.3 ng/ml. TgAb levels were measured by immunoradio-
metric method (DiaSorin); according to our laboratory reference range,
TgAb values above 100 IU/ml were considered positive. An elevated Tg
level was defined as Tg higher than 3 ng/ml, and hypothyroid was
considered a TSH level of 30 IU/ml or more after T4 withdrawal. After
two negative DWBS, additional DWBS were indicated whenever serum
Tg levels increased or tumor recurrence was suggested by clinical find-
ings. Because the presence of TgAb can falsely lower immunometric Tg
results, TgAb-positive patients were evaluated by DWBS even with
undetectable Tg levels on T4 therapy or whether rising Tg was detected.
Computerized tomography (CT), [99mTc]methoxyisobutyl-isonitrile
scan (MIBI), and/or [18F]deoxyglucose positron emission tomography
(FDG-PET) examination were performed when Tg was elevated after T4
withdrawal, but a negative TSH-stimulated DWBS scan was found. In
AbTg-positive patients, evidence of increasing levels of serial Tg, but
negative TSH-stimulated DWBS, was also an indication for CT, MIBI,
and/or FDG-PET examination. Remission was defined as low Tg levels
(undetectable on T4 therapy or 3 ng/ml after T4 withdrawal) and
negative DWBS. In AbTg-positive patients, the absence of imaging for
disease by CT, MIBI, and/or FDG-PET in the cases in which they were
indicated was necessary for remission. Criteria for persistent disease
were Tg levels greater than 3 ng/ml after T4 withdrawal and/or imaging
for disease (DWBS, CT, MIBI, or FDG-PET examination) after total or
near-total thyroidectomy and radioiodine ablation of postoperative thy-
roid remnants. Recurrence was defined as evidence of rising Tg and/or
imaging for disease after a period of remission. In patients with detect-
able Tg levels during T4 therapy and who did not meet the definition of
persistent or recurrent disease, a follow-up neck ultrasonography, Tg
measurement after T4 withdrawal and DWBS were performed to cor-
rectly classify their status as remission, persistent disease, or recurrent
disease. For persistence and recurrence analysis, only cases with data
from DWBS after ablation of postoperative thyroid remnants were eval-
uated (n  48). The median follow-up was 43 months (range, 12–120
months) after radioiodine ablation.
Immunohistochemical analysis of hPTTG
Tissue paraffin tissue sections (5 m thick) were dewaxed in xylene
and rehydrated in a series of graded alcohols. Sections were immersed
in 3% H2O2 aqueous solution for 30 min to quench endogenous perox-
idase activity, then covered with 10% normal serum in Tris-buffered
saline to block nonspecific binding sites. A rabbit polyclonal anti-hPTTG
antibody was available for this study. Specificity control experiments for
this antibody have been described previously (7, 9). Sections were in-
cubated overnight with a 1:500 dilution of primary anti-hPTTG anti-
body. After several washes in Tris buffer, secondary biotinylated anti-
rabbit IgG and streptavidin-biotin-peroxidase complex were applied
according to the manufacturer’s protocols (DakoCytomation, Glostrup,
Denmark). Visualization of the immunoreaction was completed using
3,3-diaminobenzidine as the peroxidase chromogenic substrate. The
slides were then counterstained with hematoxylin and mounted in DPX
(BDH Laboratories, Poole, UK). Sections in which primary antibody was
omitted were used as negative controls. Immunostaining was evaluated
by two independent pathologists on at least 10 microscopic fields (200),
and unequivocal moderately to intensely stained cells were counted.
Immunohistochemical expression of hPTTG was scored as high (25%
of the carcinoma cells stained), low (10–25%), or absent (10%). In
TABLE 1. Staging of DTC in 60 patients according to UICC 6th
edition
TNM stage PTC FTC Total
I
T1 N0 M0  45 yr 12 1 13
T2 N0 M0  45 yr 3 1 4
Tx N0 M0  45 yr 1 0 1
T1 N1 M0  45 yr 1 1 2
T2 N1 M0  45 yr 1 0 1
T3 N1 M0  45 yr 1 2 3
T4a N1 M0  45 yr 2 0 2
T1 N0 M0  45 yr 3 0 3
Tx N0 M0  45 yr 1 0 1
II
Tx N1 M1  45 yr 2 0 2
T2 N1 M1 45 yr 1 0 1
T3 N1 M1  45 yr 2 0 2
T4aN1M1 45 yr 3 0 3
T2 N0 M0  45 yr 2 4 6
III
T3 N0 M0  45 yr 1 1 2
T1 N1a M0  45 yr 5 0 5
Tx N1a M0  45 yr 1 0 1
IV
T4a N1 M0  45 yr 2 0 2
T2 N1 M1  45 yr 0 1 1
T4a N1 M1 45 yr 2 2 4
Tx N1 M1 45 yr 1 0 1
T, Tumor stage (T1, intrathyroidal tumor  2 cm in greatest di-
mension; T2, intrathyroidal tumor  2 cm and  4 cm in greatest
dimension; T3, intrathyroidal tumor  4 cm, or any tumor with
minimal extrathyroid extension; T4a, tumor extends beyond the thy-
roid capsule and invades sc soft tissues, larynx, trachea, esophagus,
or recurrent laryngeal nerve; T4b, tumor invades prevertebral fascia,
mediastinal vessels, or encases carotid artery; Tx, primary tumor size
cannot be assessed). N, Node stage (N0, no regional lymph node
metastasis; N1, regional lymph node metastasis; N1a, metastasis in
pretracheal and paratracheal, including prelaryngeal and Delphian
lymph nodes; N1b, metastasis in other unilateral, bilateral, or con-
tralateral cervical or mediastinal lymph nodes). M, Metastasis stage
(M0, no distant metastasis; M1, distant metastasis). UICC, Interna-
tional Union Against Cancer.
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selected cases with available frozen material, the expression of hPTTG
was confirmed by immunoblot.
Statistical methods
The association of immunohistochemical expression of hPTTG with
other tumor variables was assessed by 2 test or Fisher’s exact test, when
indicated. Student’s t test was used for comparison of tumor-related
quantitative variables between two categories of hPTTG immunostain-
ing. Tumor variables included patient age, gender, tumor size, histo-
logical type and variants, lymph node status, presence of distant me-
tastases, and TNM stage. Among histological variants, the following
were regarded as predictive of high risk (4): tall cell and diffuse scle-
rosing variants of PTC, and insular and oxyphilic variants of FTC.
Persistent disease curves were estimated by the actuarial method of
Kaplan and Meier, and the differences were analyzed by the log-rank test
of Mantel and Cox. The Cox proportional hazards model was used to
estimate the effect of hPTTG expression on persistence of disease, si-
multaneously with several prognostic factors. All tests were two-sided,
and P  0.05 was considered significant. Calculations were made with
the aid of SPSS 12.0 statistical package (SPSS, Inc., Chicago, IL).
Results
hPTTG protein expression in DTC and BNTD
All cases were examined by immunohistochemistry using
archival paraffin-embedded tissues. Of the 60 DTC evalu-
ated, 21 (35%) were low or absent, and 39 (65%) were in-
tensely immunostained with anti-hPTTG polyclonal anti-
body (Fig. 1, A–C). The staining was mainly cytoplasmic, but
nuclei were also occasionally stained. hPTTG expression in
the intensely stained category was not associated with DTC
type (PTC or FTC). Among histological subtypes of high risk
(n 14), hPTTG immunohistochemical expression was high
in 90.5% (Fig. 1, D and E); among nonhigh-risk histological
subtypes (n 46), hPTTG staining was unequivocal in 58.7%.
Nonneoplastic thyroid tissue was largely unstained, with the
exception of focally stained follicular cells. Among BNTD
cases, the expression of hPTTG was low or absent in 27
(77.1%) and high in eight (22.8%; seven of 22 multinodular
goiters and one of 13 follicular adenomas). Eleven multi-
nodular goiters and three follicular adenomas showed thy-
roiditis foci. Among unequivocally stained BNTD cases, the
expression of hPTTG was focal and associated with thyroid-
itis foci (Fig. 1F).
Association of hPTTG expression with prognostic tumor
variables of DTC
The association between immunohistochemical staining
for hPTTG in thyroid carcinoma tissue and predictive factors
of high risk is described in Table 2. hPTTG was significantly
associated with regional lymph node (P  0.01) and distant
metastasis (P  0.05). However, neither tumor size nor ag-
gressive histological variants were significantly associated
with immunohistochemical overexpression. TNM stage was
FIG. 1. Immunohistochemical demonstration of
hPTTG in thyroid normal tissues and DTCs. A,
Low magnification micrograph shows hPTTG-
immunostained tumor cells adjacent to unstained
nonneoplastic thyroid follicles. B–E, Thyroid tu-
mors expressing high levels of hPTTG. B, PTC; C,
FTC; D, tall cell carcinoma; E, insular carcinoma;
F, lymphocyte-rich nodule in BNTD with focal
hPTTG immunostaining. Bars, 100 m.
1406 J Clin Endocrinol Metab, April 2006, 91(4):1404–1409 Sa´ez et al. • hPTTG in Differentiated Thyroid Cancer
also associated with hPTTG overexpression (P  0.05), be-
cause 83.3% of tumors of advanced TNM stages, i.e. TNM III
and IV, showed unequivocal immunostaining for hPTTG.
Neither age nor gender was significantly associated with
hPTTG overexpression. The association between hPTTG
overexpression and positive TgAb at diagnosis was also as-
sessed; no significant association was found.
Association of hPTTG expression with decreased iodide
uptake in DTC
Seventeen patients with rising Tg levels after T4 with-
drawal, but negative TSH-stimulated DWBS, were found in
the persistent disease group. In nine of these patients, distant
metastases were confirmed by CT, MIBI, or FDG-PET. Im-
munohistochemical analysis showed unequivocal staining
for hPTTG in 16 tumors, and a significant association be-
tween immunohistochemical staining for hPTTG in primary
thyroid carcinoma tissue and persistent disease with nega-
tive TSH-stimulated DWBS was found (P  0.05).
Association of hPTTG expression with persistent disease
in DTC
After a mean follow-up of 51.0 months after radioiodine
ablation, persistence of the disease was demonstrated in two
of 13 patients with low hPTTG tumors (15.4%) and in 23 of
35 patients with high hPTTG tumors (65.7%). The mean time
for achieving no evidence of disease after radioiodine abla-
tion was 22.0 months [95% confidence interval (CI), 10.7–
33.4] in patients with low hPTTG tumors and 81.4 months
(95% CI, 63.9–98.8) in patients with intense hPTTG tumors.
Kaplan-Meier curves demonstrated a significantly longer
time of persistent disease after radioiodine ablation for pa-
tients who had primary tumor with unequivocal expression
of hPTTG (P 0.01) (Fig. 2). Three patients (two PTC and one
FTC) showed criteria for recurrent disease (28, 55, and 78
months after radioiodine ablation, respectively); immuno-
histochemical analysis at diagnosis showed unequivocal
staining for hPTTG in two of them and negative staining in
the last one. We also investigated whether hPTTG expression
maintained its prognostic value for persistent disease in the
presence of all of the above-mentioned variables by means of
a multivariate regression analysis (Table 3). In the series, the
expression level of hPTTG was confirmed as an independent
prognostic factor for persistent disease. For high hPTTG car-
cinomas, the adjusted relative risk was 3.0 (95% CI, 1.1–8.7;
P  0.05) in the multivariate analysis.
Discussion
In this investigation we analyzed the presence of detect-
able levels of hPTTG by immunostaining in a large series of
DTC and BNTD, evaluated its association with predictive
factors of high risk, and assessed its prognostic value. We
found hPTTG overexpression in DTC and a significant as-
sociation between hPTTG overexpression and major pheno-
type characteristics, such as nodal and distant metastasis. We
also found an association between hPTTG overexpression
and persistence of disease after total thyroidectomy and ra-
dioiodine ablation, which is particularly strong in persistent,
but undetectable, disease by DWBS. Thus, immunohisto-
chemical analysis of hPTTG might be a powerful tool in the
determination of tumor aggressiveness and persistent dis-
ease in DTC.
FIG. 2. Persistent disease in a series of 48 patients with DTC ac-
cording to the immunohistochemical expression of hPTTG. Kaplan-
Meier analysis of patients showing either high (a; n  35) or low (b;
n  13) expression of hPTTG was performed. The P value was de-
termined with the log-rank test of Mantel and Cox.
TABLE 2. Association of hPTTG immunohistochemical expression
with DTC prognostic variables
Variables
hPTTG expression
P value
Low High
Sex, n (%)
Male 2 (15.4) 11 (84.6) 0.1
Female 19 (40.4) 28 (59.6)
Age, yr (mean  SD) 49.0  16.9 43.1  19.9 0.3
Histological type, n (%)
PTC 16 (34.0) 31 (66.0) 0.8
FTC 5 (38.5) 8 (61.5)
Histological variants, n (%)
Aggressivea 2 (9.5) 12 (90.5) 0.1
Conventional 19 (41.3) 27 (58.7)
Tumor size, cm (mean  SD) 2.4  1.9 3.1  1.5 0.1
Lymph node metastasis, n (%)
Yes 6 (20.0) 24 (80.0) 0.005
No 1 (56.7) 13 (43.3)
Distant metastasis, n (%)
Yes 1 (7.1) 13 (92.9) 0.02
No 20 (43.5) 26 (56.5)
TNM staging, n (%)
Stage I or II 19 (45.2) 23 (54.8) 0.04
Stage III or IV 3 (16.7) 15 (83.3)
a Aggressive variants include insular and oxyphilic FTC, and tall
cell and sclerosing diffuse PTC.
TABLE 3. Multivariate analysis of persistent disease in DTC
determined by Cox’s proportional hazards model
Variables RR 95% CI P value
Sex (male vs. female) 1.8 0.3–9.1 0.5
Age (45 vs.  45 yr) 1.1 0.5–2.9 0.8
Histological type (FTC vs. PTC) 0.8 0.3–2.5 0.7
Histological variants (aggressivea
vs. conventional)
0.4 0.1–2.3 0.3
Tumor size (cm) 1.0 0.7–1.5 0.8
Lymph node metastasis (yes vs. no) 1.8 0.6–5.0 0.3
Distant metastasis (yes vs. no) 2.7 0.3–24.3 0.4
hPTTG expression (high vs. low) 3.0 1.1–8.7 0.04
RR, Adjusted relative risk.
a Aggressive variants include insular and oxyphilic FTC, and tall
cell and sclerosing diffuse PTC.
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Heaney et al. (16) first reported increased hpttg mRNA
expression in a subset of FTC, but not in four of eight PTC,
examined by Northern blot analysis, suggesting that hpttg
may play a role in the molecular events implicated in the
divergence of FTC vs. PTC phenotypes. Contrarily, we found
no difference in the pattern of hPTTG expression by immu-
nostaining between FTC and PTC. Our results are in agree-
ment with those of Boelaert et al. (17), who described pre-
translational hpttg overexpression in both FTC and PTC
compared with normal and hyperplastic thyroid tissue by a
quantitative RT-PCR approach. Even though no significant
association between the expression of hpttgmRNA and TNM
status was evident, an association between hpttg mRNA and
early tumor recurrence was suggested (17). In the present
study the expression level of hPTTG was confirmed as an
independent prognostic factor for persistent disease. The
association between hPTTG overexpression and other clin-
ically relevant outcomes, such as cancer-related death and
recurrence, could not be evaluated in our study. Patients with
DTC have 10-yr cancer-specific mortality rates less than 10%
(2). Because of its high survival rates and prolonged clinical
course, cancer-related death is an outcome only available in
epidemiological studies including long-term follow-up of a
large series of DTC. It has been suggested that most cases of
recurrence are actually cases of persistent disease that have
progressed to the point of detection (20). Current sensitive Tg
assays allow for the early detection and treatment of cases of
persistent disease, thus diminishing the risk of progression.
It is possible that the criteria for persistent disease defined in
our protocol contributed to the small rate of recurrent dis-
ease, which did not allow us to consider this a main outcome.
Thus, according to our results, hPTTG expression represents
a molecular marker of worse prognosis in DTC. The immu-
nohistochemical method allows easy identification of cells
overexpressing hPTTG. Tumors that expressed high levels of
hPTTG showed an association with advanced TNM stages.
Increased hpttg expression has been associated with vascular
invasion and lymph node metastasis (14). Also, hpttg has
been included in a set of genes whose expression can predict
a metastastic phenotype in multiple tumor types (21). hPTTG
induces the expression of vascular endothelial growth factor
(22), which is considered the most important angiogenic
factor involved in tumor neovascularization.
The physiopathological mechanisms leading to persis-
tence, recurrence, and progression of thyroid cancer are
largely unknown. It is thought that one mechanism relates in
part to decreased sodium-iodide symporter (NIS) expression
(23). NIS is an integral membrane glycoprotein that mediates
active iodine transport into thyroid cells as the first step in
thyroid hormone biosynthesis (24). The ability of thyroid
cells to accumulate iodine has been used as an effective
means for diagnostic and therapeutic doses of radioiodine to
localize and destroy DTC and their metastases. Thus, pre-
diction of a lack of responsiveness to radioiodine therapy
would be extremely useful in the follow-up of these patients,
an event that occurs in about one third of patients with DTC
(25). hPTTG overexpression in rat FRTL5 thyroid cells and
primary human thyroid cell cultures causes in vitro trans-
formation, decreased iodine uptake, and reduced NIS ex-
pression (16). In our series, 17 of 25 patients with persistent
disease after radioiodine ablation showed elevated serum Tg
levels and undetectable iodine uptake; nearly all these cases
showed overexpression of hPTTG in primary DTC tumors.
Interestingly, aggressive clinical behavior in tumors with loss
of capacity to respond to radioiodine therapy could not be
predicted according to histological or TNM staging criteria.
According to Heaney et al. (16), we hypothesize that hPTTG
overexpression might play a role in the loss of capacity to
accumulate iodine and respond to radioiodine therapy in
noniodine-transporting DTC. Even though more studies are
needed, analysis of immunohistochemical expression could
be useful in the prediction of loss of capacity to respond to
radioiodine therapy in DTC.
In DTC, numerous staging classification systems have
been proposed to predict outcomes and to select individu-
alized therapy. Recently, two consensus statements have
been proposed in the follow-up of low-risk patients with
DTC (26, 27). Specific molecular markers of tumor prognosis
would be extremely useful in the classification of high- and
low-risk DTC and could help in designing follow-up proto-
cols. Immunohistochemical expression of hPTTG might be a
powerful tool in the determination of tumor aggressiveness
in DTC.
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